Comparative Analysis of Isavuconazole DDIs With Other Azole Antifungal Drugs and PBPK Model-Informed Dosing Recommendations for Anticancer Drugs.

ABSTRACT: Isavuconazole is a broad-spectrum triazole approved for the treatment of invasive aspergillosis or mucormycosis in adults and children aged ≥ 1 year. Current prescribing information lacks guidance regarding the co-administration of isavuconazole with anticancer drugs-limited by the availability of clinical drug-drug interaction (DDI) data in the patient population. This study utilized physiologically-based pharmacokinetic (PBPK) modeling to evaluate the DDI risk of isavuconazole compared with other azoles and provide dosing recommendations when co-administered with anticancer drugs (ibrutinib, venetoclax, and midostaurin). PBPK models were developed in the Simcyp simulator using physiochemical properties, in vitro, and clinical pharmacokinetic data. The model well-predicted isavuconazole p

SUBMITTER: Goosen TC 

PROVIDER: S-EPMC12706401 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature